Ken Griffin Veracyte, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$18.86 - $23.55 $514,878 - $642,915	-27,300 Reduced 88.93%	3,400 $73,000
Q1 2024 May 15, 2024	BUY	$21.0 - $29.1 $8,400 - $11,640	400 Added 1.32%	30,700 $680,000
Q4 2023 Feb 14, 2024	BUY	$19.72 - $28.68 $368,764 - $536,316	18,700 Added 161.21%	30,300 $833,000
Q3 2023 Nov 14, 2023	SELL	$22.33 - $29.92 $207,668 - $278,256	-9,300 Reduced 44.5%	11,600 $259,000
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $54,496 - $70,174	2,600 Added 14.21%	20,900 $532,000
Q1 2023 May 15, 2023	BUY	$20.58 - $27.89 $207,857 - $281,689	10,100 Added 123.17%	18,300 $408,000
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $125,542 - $245,508	8,200 New	8,200 $194,000

270

78.7M

42.3K

18.2K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.67B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.